References

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. Ca Cancer J Clin 2000;50:7-33.

2. Keating MJ. Chronic lymphocytic leukemia. Sem Oncol 1999;26(suppl 14):107-114.

3. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000;25:717-722.

4. Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. Sem Oncol 1998;25:19-26.

5. Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 1996;87:2615-2620.

6. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999;17:399-408.

7. Geisler CH, Larsen JK, Hansen NE, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991;78:1795-1802.

8. Weisenburger DD, Armitage JO. Mantle cell lymphoma—an entity comes of age. Blood 1996;87:4483-4494.

9. Damle RN, Wasil T, Fais F, et al. Immunoglobulin V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.

10. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody Rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-3908.

11. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995;85:3556-3565.

12. Vincent AM, Cawley JC, Burthem J. Integrin function in chronic lymphocytic leukemia. Blood 1996;87: 4780-4788.

13. Hashimoto S, Chiorazzi N, Gregersen PK. Alternative splicing of CD79a (Ig-alpha/mb-1) and CD79ß (Ig-beta/ B29) RNA transcripts in human B cells. Mol Immunol 1995;32:651-659.

14. Pan PY, Rothman P. IL-4 receptor mutations. Curr Opin Immunol 1999;11:615-620.

15. Link BK, Kostelny SA, Cole MS, Fusselman WP, Tso JY, Weiner GJ. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. Intl J Cancer 1998;77:251-256.

16. Pospisil R, Mage RG. CD5 and other superantigens as 'ticklers' of the B-cell receptor. Immunol Today 1998; 19:106-108.

17. Green LJ, Mould AP, Humphries MJ. The integrin beta subunit. Intl J Biochem Cell Biol 1998;30:179-184.

18. Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity 1999;11:191-200.

19. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48:673-683.

20. Mongini PK, Vilensky MA, Highet PF, Inman JK. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J Immunol 1997; 159:3782-3791.

21. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Ann Rev Immunol 1997;15:481-504.

22. Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, et al. Structure and functions of CD23. Intl Rev Immunol 1997; 16:113-128.

23. Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385-3395.

24. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998;70:1-81.

25. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today 2000;21: 204-206.

26. Green LJ, Mould AP, Humphries MJ. The integrin beta subunit. Intl J Biochem Cell Biol 1998;179-184.

27. Konopleva M, Rissling I, Andreeff M. CD38 in hematopoietic malignancies. Chem Immunol 2000;75:189-206.

28. Seveau S, Keller H, Maxfield FR, Piller F, Halbwachs-Mecarelli L. Neutrophil polarity and locomotion are associated with surface redistribution of leukosialin (CD43), an antiadhesive membrane molecule.

29. Bajorath J. Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 2000;39:103-111.

30. Justement LB. The role of CD45 in signal transduction. Adv Immunol 1997;66:1-65.

31. Mateo V, Lagneaux L, Bron D, et al. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nature Med 1999;5:1277-1284.

32. Seiffert M, Cant C, Chen Z, et al. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 1999;94: 3633-3643.

33. Hayashida K, Shimaoka Y, Ochi T, Lipsky PE. Rheumatoid arthritis synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells in a CD49/CD29-CD106-dependent mechanism. J Immunol 2000; 164:1110-1116.

34. Berney SM, Schaan T, Alexander JS, et al. ICAM-3 (CD50) cross-linking augments signaling in CD3-activated peripheral human T lymphocytes. J Leukocyte Biol 1999;65:867-874.

35. Focarelli R, Della Giovampaola C, Seraglia R, et al. Biochemical and MALDI analysis of the human sperm antigen gp20, homologue of leukocyte CD52. Biochem Biophys Res Commun 1999;258:639-643.

36. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leukemia Res 1998;22:185-191.

37. Hubbard AK, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radical Biol Med 2000;28:1379-1386.

38. Brodbeck WG, Kuttner-Kondo L, Mold C, Medof ME. Structure/function studies of human decay-accelerating factor. Immunology 2000;101:104-111.

39. Qian YM, Qin X, Miwa T, Sun X, Halperin JA, Song WC. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J Immunol 2000;165:2528-2534.

40. Elangbam CS, Qualls CW, Dahlgren RR. Cell adhesion molecules—update. Vet Pathol 1997;34:61-73.

41. Jacquot S. CD27/CD70 interactions regulate T dependent B cell differentiation. Immunol Res 2000;21:23-30.

42. Adachi T, Wakabayashi C, Nakayama T, Yakura H, Tsubata T. CD72 negatively regulates signaling through the antigen receptor of B cells. J Immunol 2000;164:1223-1229.

43. Gordon MS, Kato RM, Lansigan F, Thompson AA, Wall R, Rawlings DJ. Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. Proc Natl Acad Sci USA 2000; 97:5504-5509.

44. Carpenito C, Pyszniak AM, Takei F. ICAM-2 provides a costimulatory signal for T cell stimulation by allogeneic class II MHC. Scand J Immunol 1997;45:248-254.

45. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93:151-153.

46. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567-1574.

47. Keating MJ, Byrd J, Rai K, et al. Multicenter study of campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine. Blood 1999;94(suppl 1):705a.

48. Kennedy B, Rawstron AC, Evans P, et al. Campath-1H therapy in 29 patients with refractory CLL: true complete remission is an attainable goal. Blood 1999;94(suppl 1):603a.

49. Ferrajoli A, O'Brien S, Kurzrock R, et al. Phase II clinical trial of Campath-1H in refractory hematologic malignancies expresesing the surface antigen CD52. Proc ASCO 2000;19:8a.

50. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-191.

51. Pruzanski W, Urowitz MB, Grouix B, Vadas P. Induction of TNF-alpha and proinflammatory secretory phos-pholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis. J Rheumatol 1995;22:1816-1819.

52. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-237.

53. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH-1H: involvement of CD16 (FcgammaRIII) and CD11a/CD18(LFA-1) on NK cells. J Clin Invest 1996;98:2819-2826.

54. Byrd JC, Shinn CA, Jansure J, et al. Campath-1H induces apoptosis in human chronic lymphocytic leukemia cells in vitro independent of complement mediated lysis or Fc receptor ligation. Blood 1999;94(suppl 1):126a.

55. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders:evaluation of response on 48 patients. Eur J Haematol 1999;62:76-82.

56. Byrd JC, Grever MR, Davis B, et al. Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a feasible and active regimen. Blood 1999;94(suppl 1):704a.

57. O'Brien S, Freireich E, Andreeff M, Lerner S, Keating M. Phase I/II study of rituxan in chronic lymphocytic leukemia (CLL). Blood 1998;92(suppl 1):105a.

58. Keating MJ, O'Brien S, Lerner S, et al. Combination chemo-antibody therapy with fludarabine (F), cytclophosphamide (C) and rituximab (R ) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL). Blood 2000;96(suppl 1):514a.

59. Garcia-Manero G, O'Brien S, Cortes J, et al. Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 2000;96(suppl 1):757a.

60. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998;51:364-369.

61. Berinstein N, Grillo-Lopez A, White CA, et al. Association of serum rituximab concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodkgin's lymphoma. Ann Oncol 1998;9:1-7.

62. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemia B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998;92:2387-2396.

63. Demiden A, Hanna N, Hariharan H. Chimeric anti-CD20 antibody (IDEC-C2B8) is apoptotic and sensitizes drug resistant human B-cell lymphomas and AIDS related lymphomas to the cytotoxic effect of CDDP, VP-16, and toxins. J FASEB 1995;9:206a.

64. Link BK, Wang H, Byrd JC, et al. Phase I trial of humanized 1D10 (Hu1D10) monoclonal antibody targetting class II molecules in patients with relapsed lymphoma. Proc ASCO 2000;19:24a.

65. Leonard JP, Coleman M, Chadburn A, et al. Epratuzumab (HLL2, anti-CD22 humanized monoclonal antibody) is an active and well-tolerated therapy for refractory/relapsed diffuse large B-cell non-Hodgkin's lymphoma (NHL). Blood 2000;96(suppl 1):578a.

66. Foss FM, Raubitscheck A, Mulshine JL, et al. Phase I study of the pharmacokinetics of a radioimmuno-conjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 1998;4: 2691-2700.

67. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF. Effect of Lym-1 radioimmuno-conjugate on refractory chronic lymphocytic leukemia. Cancer 1994;73:1425-1432.

68. Vose JM, Colcher D, Gobar L, et al. Phase I/II trial of multiple dose 131Iodine-Mab LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymph 2000;38:91-101.

69. Wiseman GA, White CA, Witzig TE, et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999;5(suppl 10):3281s-3286s.

70. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-1266.

71. DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares aCF, DeNardo SJ. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:533-541.

72. Uckun FM, Messinger Y, Chen CL, et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res 1999;5:3906-3913.

73. Choe S, Bennet MH, Fuji G, et al. The crystal structure of diphtheria toxin. Nature 1992;357:216-222.

74. Allured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Angstroms. Proc Natl Acad Sci USA 1986;83:1320-1324.

75. Rutenber E, Robertus JD. Structure of ricin B-chain at 2.5 Angstrom resolution. Proteins 1991;10:260-269.

76. Monzingo AF, Collins EJ, Ernst SR, Irvin JD, Robertus JD. The 2.5 Angstrom structure of pokeweed antiviral protein. J Mol Biol 1993;233:705-715.

77. Brooke JS, Cha J-H, Eidels L. Diphtheria toxin:receptor interaction: association, dissociation, and effect of pH. Biochem Biophys Res Commun 1998;248:297-302.

78. Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, Saelinger CB. The alpha2-macroglo-bulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 1992;267:12,420-12,423.

79. Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham MC. Ricin toxin contains three galactose-binding sites located in B chain subdomains 1a, 1ß, and 2y. Biochem 1996;35:14,747-14,756.

80. Lemichez E, Bomsel M, Devilliers G, et al. Membrane translocation of diphtheria toxin fragment A exploits early to late endosome trafficking machinery. Mol Microbiol 1997;23:445-457.

81. Rapak A, Falnes PO, Olsnes S. Retrograde transport of mutant ricin to the endoplasmic reticulum with subsequent translocation to cytosol. Proc Natl Acad Sci USA 1997;94:3783-3788.

82. Oh KJ, Zhan H, Cui C, Hideg K, Collier RJ, Hubbell WL. Organization of diphtheria toxin T domain in bilayers: a site-directed spin labeling study. Science 1996;273:810-812.

83. Wilson KS, Noller HF. Molecular movement inside the translational engine. Cell 1998;92:337-349.

84. Van Ness BG, Howard JB, Bodley JW. ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products. J Biol Chem 1980;255: 10,710-10,716.

85. Endo Y, Tsurugi K, Lambert JM. The site of action of six different ribosome-inactivating proteins from plants on eukaryotic ribosomes: the RNA N-glycosidase activity of the proteins. Biochem Biophys Res Commun 1988;150:1032-1036.

86. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Cytotoxic activity of disul-fide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 2000;6:1476-1487.

87. Van Horssen PJ, van Oosterhout YV, Evers S, et al. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells. Leukemia 1999;13:241-249.

88. Kreitman RJ, Chaudhary VK, Kozak RW, FitzGerald DJP, Waldmann TA, Pastan I. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood 1992;80:2344-2352.

89. Kreitman RJ, Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk Lymph 1994;13:1-10.

90. Re GG, Waters C, Poisson L, Willingham MC, Sugamura K, Frankel AE. Interleukin-2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res 1996;56: 2590-2595.

91. Waters CA, Bach PA, Snider CE, et al. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur J Immunol 1990;20:785-791.

92. Sweeney EB, Foss FM, Murphy JR, vanderSpek JC. Interleukin 7 (IL-7) receptor-specific cell killing by DAB389IL-7: a novel agent for the elimination of IL-7 receptor positive cells. Bioconjugate Chem 1998;9:201-207.

93. Faguet GB, Agee JF. Four ricin chain A-based immunotoxins directed against the common chronic lymphocytic leukemia antigen: in vitro characterization. Blood 1993;82:536-543.

94. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blattler WA. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res 1991;51:6236-6242.

95. Uckun FM, Evans WE, Forsyth CJ, et al. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995;267:886-891.

96. Van Horssen PJ, Oosterhout YVJM, Evers S, et al. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells. Leukemia 1999;13:241-249.

97. Bolognesi A, Tazzari PL, Olivieri F, et al. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. Br J Haematol 1998;101:179-188.

98. Hertler AA, Schlossman DM, Borowitz MJ, Blythman HE, Casellas P, Frankel AE. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. Int J Cancer 1989;43:215-219.

99. Hertler AA, Schlossman DM, Borowitz MJ, et al. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Resp Mod 1988;7:97-113.

100. Grossbard ML, Lambert JM, Goldmacher VS, et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993;11:726-737.

101. Grossbard ML, Freedman AS, Ritz J, et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase

1 trial of daily bolus infusion. Blood 1992;79:576-585.

102. LeMaistre CF, Meneghetti C, Rosenblum M, et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992;79:2547-2554.

103. LeMaistre CF, Rosenblum MG, Reuben JM, et al. Therapeutic effects of genetically engineered Toxin (DAB486IL-2) in patients with chronic lymphocytic leukaemia. Lancet 1991;337:1124-1125.

104. LeMaistre CF, Craig FE, Meneghetti C, et al. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-

2 in hematologic cancers. Cancer Research 1993;53:3930-3934.

105. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1622-1636.

106. Kreitman RJ, Wilson WH, Stetler-Stevenson M, et al. High complete remission rate in chemotherapy-refractory classic or variant hairy cell leukemia induced by the anti-CD22 recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22). Blood 2000;96(suppl 1):577a.

107. Chaudhary VK, FitzGerald DJ, Pastan I. A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem Biophys Res Commun 1991;180:545-551.

108. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 1995;307:29-37.

109. Hessler JL, Kreitman RJ. An early step in Pseudomonas exotoxin action is removal of terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 1997;36:14,577-14,582.

110. Keppler-Hafkemeyer A, Kreitman RJ, Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Intl J Cancer 2000;87:86-94.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment